Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 17 July 2017

Ratos AB: Daniel Spasic leaves his position as CEO of TFS


Ratos AB: Daniel Spasic leaves his position as CEO of TFS

PRESS  RELEASE  17 July 2017


Daniel Spasic has chosen to leave his position as CEO of Ratos's subsidiary TFS, an international Contract Research Organisation (CRO), which conducts clinical trials for pharmaceutical, biotechnology and medtech companies. James Utterback has been appointed acting CEO until a permanent CEO has been recruited.

In recent years, TFS has focused on therapeutic expertise, internationalisation, organisation and service offerings. Daniel Spasic, founder of TFS and the company's CEO since 1996, has been an important contributor to this strategic focus. Daniel has now chosen to leave the company and James Utterback, an advisor to the Board of Directors of TFS with extensive experience in the pharmaceuticals industry, has been appointed acting CEO as of 14 August. The recruitment process to find a permanent replacement has begun.


"As the founder of TFS and for his 20 years as CEO, Daniel has applied his industry expertise to successfully build and develop TFS into an international clinical contract research company. Under Daniel's leadership, TFS has positioned itself as a company with a focus on small and medium life science customers. Now, at a natural point in time, when TFS is taking the next step on its growth journey, with a clear set of goals and a well-defined strategy, Daniel has chosen to leave his position as CEO of the company," says Mikael Norlander, Senior Investment Director at Ratos and company executive for TFS. 


Daniel will remain as a key owner of TFS, with 40% of the shares.


Ratos became a part-owner of TFS in 2015. On behalf of its customers, the company now conducts clinical trials in more than 40 countries and works with a broad international customer base of leading research companies. The company has approximately 750 employees and professional fee revenues for the rolling 12 months at 31 March 2017 amounted to EUR 60.6m and EBITA was
EUR 6.5m.




For further information, please contact:

Mikael Norlander, Senior Investment Director, +46 8 700 17 00


Ratos is an investment company that owns and develops unlisted medium-sized companies in the Nordic countries. Our goal as an active owner is to contribute to long-term and sustainable business development in the companies we invest in and to make value-generating transactions. Ratos's portfolio consists of 16 medium-sized Nordic companies and the largest segments in terms of sales are Construction, Industrials and Consumer goods/Commerce. Ratos is listed on Nasdaq Stockholm and has a total of approximately 14,000 employees.

Press Release

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Ratos, Box 1661
Drottninggatan 2, Stockholm 111 96, Sverige
If you would like to unsubscribe and stop receiving these e-mails click here.